Ravulizumab exposure in early pregnancy [PDF]
Annals of HematologyBefore complement inhibitors were available, pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) was associated with considerable mortality, mainly due to thromboembolism.
Wolfgang Füreder +3 more
doaj +4 more sources
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab [PDF]
Annals of Clinical and Translational NeurologyObjective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG)
Guido Wabnitz +2 more
exaly +3 more sources
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study [PDF]
Annals of HematologyRavulizumab is a second-generation C5i engineered from eculizumab to achieve immediate, complete, and sustained inhibition of terminal complement activity in PNH.
Anna Paola Iori +35 more
doaj +2 more sources
Ravulizumab for the treatment of myasthenia gravis
Expert Opinion on Biological Therapy, 2023 Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response.
Renato Mantegazza, Fiammetta Vanoli
exaly +4 more sources
Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
Neuropsychiatric Disease and Treatment, 2023 Tuan Vu,1 Heinz Wiendl,2 Masahisa Katsuno,3 Stephen W Reddel,4 James F Howard Jr5 1Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA; 2Department of Neurology with Institute of Translational Neurology ...
Vu T +4 more
doaj +3 more sources
Case Report: COVID-19 unmasks factor H mutation-driven hemolytic uremic syndrome in a previously undiagnosed septuagenarian kidney transplant recipient [PDF]
Frontiers in MedicineThrombotic microangiopathy (TMA) after kidney transplantation presents a significant diagnostic and therapeutic challenge. Complement-mediated thrombotic microangiopathy (CM-TMA), caused by dysregulation of the alternative complement pathway, is ...
Michael Fink +5 more
doaj +2 more sources
Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab
Kidney International ReportsIntroduction: Atypical hemolytic uremic syndrome (aHUS) is a progressive rare disease that, if untreated, can result in severe organ damage and death.
Franz Schaefer +2 more
exaly +3 more sources
Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database [PDF]
Frontiers in ImmunologyBackgroundRavulizumab is a long-acting C5 complement inhibitor that provides sustained suppression of the complement pathway. It is currently approved by the US Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis ...
Yue Zhou +3 more
doaj +2 more sources
Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study) [PDF]
Kidney MedicineRationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab, a complement C5 inhibitor (C5i), is approved for aHUS; however, published evidence in
Ramy Magdy Hanna +8 more
doaj +2 more sources
Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment [PDF]
Blood Advances: In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality.
Austin G. Kulasekararaj +10 more
doaj +2 more sources